XPro™ Breakthrough Treatment Offers Hope for Alzheimer’s Disease
XPro™ Treatment and Its Impact on Alzheimer’s Disease
It's established that traumatic brain injury (TBI) can significantly increase the risk of developing Alzheimer’s disease (AD). Recent advancements in understanding this phenomenon have led to promising studies surrounding XPro™, a novel treatment aimed at alleviating some of the effects associated with TBI and reducing the likelihood of AD pathology.
Research Findings on XPro™
INmune Bio, Inc. (NASDAQ: INMB), a company dedicated to utilizing the innate immune system for disease treatment, has partnered with Dr. Kirsty Dixon from Virginia Commonwealth University to investigate the links between TBI and AD. Their recent study, presented in a poster session at a notable symposium, unveiled how TBI leads to increased amyloid deposits in vulnerable animals. Precisely, the treatment using XPro™ significantly lowered the formation of amyloid beta, a key contributor to neurodegeneration.
The Role of TNF in Alzheimer’s Progression
One of the critical underlying factors in Alzheimer’s is neuroinflammation, particularly involving the cytokine Tumor Necrosis Factor (TNF). This inflammatory cytokine plays a role in accelerating AD progression. The enzyme ?-secretase (BACE1), which stemmed from amyloid precursor protein (APP), is pivotal in forming neurotoxic amyloid beta. By targeting the pathway activated by TNF, researchers believe that they can reduce amyloid production and consequently, neuronal death.
XPro™’s Mechanism of Action
The study revealed that following TBI, there was a noticeable spike in markers such as TNFR1, BACE1, and A?42 within three days. However, administering XPro™ a mere thirty minutes post-injury curbed the activity of solTNF/TNFR1, even counteracting increases in detrimental markers associated with neurodegeneration. The outcome was a reduction in intracellular amyloid accumulation and marked improvements in neurological functioning among treated subjects.
Implications for Alzheimer’s Disease Treatment
Dr. Dixon commented on the outcomes, highlighting the treatment’s potential to lower the risk of AD by addressing the underlying inflammatory mechanisms ignited by TBI. Elliott Mufson, a collaborator on the study, emphasized that the XPro™ treatment could be a breakthrough for patients suffering from neurobehavioral issues arising from brain injuries and aging-related neurodegenerative conditions.
The Importance of Addressing TBI in the Elderly
Dr. RJ Tesi, CEO of INmune Bio, stressed the urgency of effectively treating CNS pathology resulting from traumatic brain injuries, particularly among the elderly. Falls and other TBIs can exacerbate symptoms of dementia and accelerate Alzheimer's onset, making treatment paramount in preserving cognitive health in these populations.
What is XPro™?
XPro™ stands out from traditional TNF inhibitors as it selectively neutralizes soluble TNF while preserving the function of membrane-bound TNF, offering a unique solution to diminishing neuroinflammation and its adverse effects on cognitive function.
Future Research and Development
As INmune Bio continues its commitment to advancing clinical trials, the potential for XPro™ to enhance neurological health and improve patient outcomes is becoming increasingly hopeful. Their innovative approach to managing cognitive impairments through targeted treatment could pave the way for novel therapies to combat Alzheimer’s and other neurodegenerative conditions.
About INmune Bio
As a publicly traded company on NASDAQ under the ticker INMB, INmune Bio is at the forefront of biotechnology, focusing on developing treatments that target the innate immune response. With several product platforms in clinical trials, their work is significantly geared towards addressing chronic inflammatory diseases and neurobiological health.
Frequently Asked Questions
What is XPro™ and how does it work?
XPro™ is an innovative treatment designed to neutralize soluble TNF without impairing membrane-bound TNF, aimed at reducing neuroinflammation linked to Alzheimer’s and improving cognitive outcomes.
How does traumatic brain injury relate to Alzheimer’s disease?
Traumatic brain injury is a significant risk factor for developing Alzheimer’s as it accelerates neuroinflammation, leading to increased amyloid deposition and cognitive decline.
What were the key findings from the recent study?
The study revealed that XPro™ treatment significantly reduced amyloid formation after TBI and improved neurological function, indicating its potential efficacy in preventing Alzheimer’s pathology.
Who conducted the research on XPro™?
The research was conducted in collaboration between INmune Bio and Dr. Kirsty Dixon at Virginia Commonwealth University, showcasing the interaction between TBI and Alzheimer’s disease.
What are the implications of these findings?
The findings suggest that addressing neuroinflammation through treatments like XPro™ could offer new strategies for preventing Alzheimer’s disease, particularly in populations at risk due to age or previous brain injuries.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
